All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
How close are we to offering treatment tailored to mutational profile?
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile.
How close are we to offering treatment tailored to mutational profile?
Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to determine treatment options. He discusses target therapies that are available to patients, including
- midostaurin (FLT3 inhibitor) for the frontline setting
- ivosidenib (IDH1 inhibitor) for the relapsed/refractory (R/R) setting
- enasidenib (IDH2 inhibitor) for the R/R setting
- gilteritinib (FLT3 inhibitor) for the R/R setting
He concludes by discussing other novel agents that have shown efficacy in the treatment of AML, including venetoclax and gemtuzumab ozogamicin.
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?